ClinicalTrials.gg
Enrolling by invitationNCT04770571Updated Dec 22, 2025

Posterior Cervical Fixation Study

An observational study in Degenerative Disc Disease, Craniocervical Injuries and Cervical Radiculopathy, sponsored by NuVasive. Enrolling by invitation at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by NuVasive (part of Globus Medical) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate the safety and performance of occipito-cervico-thoracic spine surgery using posterior fixation as measured by reported complications, radiographic outcomes, and patients reported outcomes (PROs).This study is being undertaken to identify possible residual risks and to clarify mid-to long-term clinical performance that may affect the benefit/risk ratio of posterior fixation systems.

Read the detailed description

This study is a prospective, uncontrolled, multicenter study to evaluate the safety and performance of select occipito-cervico-thoracic posterior fixation systems in patients who undergo posterior fixation fusion surgery. Consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with traumatic, reconstructive, and/or tumor conditions in the craniocervical, cervical, and/or upper thoracic spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled in the study, subjects will undergo posterior occipito-cervico-thoracic fixation surgery using one of the NuVasive posterior fixation systems (Vuepoint II OCT or Reline-C) based on the surgeon's standard of care. At least 150 subjects (a minimum of 75 in each implant arm) will be enrolled and will be followed for 24 months after the surgery.

02

Conditions studied

  • Degenerative Disc Disease
  • Craniocervical Injuries
  • Cervical Radiculopathy
  • Cervical Disc Disease
  • Cervical Fusion
  • Cervical Spine Disease
  • Cervical Myelopathy
  • Cervical Instabilities Spine
  • Thoracic Injury
03

In context

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

This study's planned enrollment of 150 is above the median of 119 across 170 observational studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

NuVasive is the lead sponsor of 38 studies on the registry; 8 are open to participants now.

First submitted before NuVasive became part of Globus Medical.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Enrolled Population

The Enrolled Population will include all subjects who meet the criteria for enrollment, specifically, those subjects who:

  • Satisfied the inclusion and exclusion criteria,
  • Signed the informed consent, and
  • Underwent the surgical procedure, as defined in this protocol.

Evaluable Population

The Evaluable Populations will include all subjects who:

  • Were included in the Enrolled Populations,
  • Completed the study, and
  • Had no major protocol deviations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are ≥18 years of age at the time of consent
  2. Have planned craniocervical, cervical (C1 to C7), and/or upper thoracic (T1-T3) spine surgery using posterior fixation planned for treatment of any of the following conditions:

    1. traumatic spinal fractures and/or traumatic dislocations
    2. instability or deformity
    3. failed previous fusions (e.g., pseudoarthrosis)
    4. tumors involving the cervical spine
    5. degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability
  3. Using one of the following posterior occipito-cervico-thoracic fixation systems (NuVasive, Inc, San Diego, CA):

    1. Vuepoint II OCT
    2. Reline-C
  4. Able to undergo surgery based on physical exam, medical history, and surgeon judgment
  5. Understands the conditions of enrollment and is willing to sign an form to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patient is involved in active litigation relating to the spine (workers' compensation claim is allowed if it is not contested)
  2. Use of bone growth stimulators postoperatively
  3. Active smoking within 6 weeks of surgery
  4. Patient has known sensitivity to materials implanted
  5. Systemic or local infection (latent or active) or signs of local inflammation
  6. Patient has inadequate bone stock or quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment
  7. Pregnant, or plans to become pregnant
  8. Patient is a prisoner
  9. Patient is participating in another clinical study that would confound study data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vuepoint II OCT

    Device: observational study

  • Reline-C

    Device: observational study

Interventions

  • Deviceobservational study

    observational

06

What researchers measure

Primary outcomes

  1. Complications of Posterior Fixation System

    Rate of complications (i.e., safety) attributable to the use of the associated posterior fixation system.

    Time frame: 24 months

  2. Radiographic Success

    The proportion of subjects with apparent radiographic success at: 1. Latest timepoint available for patients undergoing surgery to treat advanced stage tumors 2. 24 months postoperative for subjects undergoing surgery to treat instabilities, traumatic spinal fractures, failed previous fusions, or degenerative disease

    Time frame: 24 months

Secondary outcomes

  1. Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline for neck/arm pain measured by visual analog scale (VAS).

    Neck and arm pain measured using a visual analog scale (VAS) will be assessed to determine the percentage of subjects who meet MCID (2.5 points and 2.5 points respectively) where 0 is "No Pain" and 10 is "Unbearable Pain".

    Time frame: 24 months

  2. Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline for disability measured by the neck disability index.

    Disability measured by the neck disability index (NDI) will be assessed to determine the percentage of subjects who meet MCID (7.5 points) where a higher score on the NDI indicates a more severe disability.

    Time frame: 24 months

  3. Percentage of subjects meeting minimal clinically important difference (MCID) as compared to baseline measured by overall physical and mental health from PROMIS-10.

    Overall physical and mental health measured by PROMIS-10 will be assessed to determine the percentage of subjects who meet MCID (5 points). PROMIS-10 scoring uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.

    Time frame: 24 months

  4. Percentage of subjects meeting substantial clinical benefit (SCB) for neck/arm pain as compared to baseline for neck/arm pain measured by visual analog scale (VAS).

    Neck and arm pain measured using a visual analog scale (VAS) will be assessed to determine the percentage of subjects who meet SCB (3.5 points) where 0 is "No Pain" and 10 is "Unbearable Pain".

    Time frame: 24 months

  5. Percentage of subjects meeting substantial clinical benefit (SCB) as compared to baseline for disability measured by the neck disability index.

    Disability measured by the neck disability index (NDI) will be assessed to determine the percentage of subjects who meet SCB (9.5 points) where a higher score on the NDI indicates a more severe disability.

    Time frame: 24 months

  6. Percentage of subjects meeting substantial clinical benefit (SCB) as compared to baseline measured by overall physical and mental health from PROMIS-10.

    Overall physical and mental health measured by PROMIS-10 will be assessed to determine the percentage of subjects who meet SCB (6.8 points). PROMIS-10 scoring uses a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.

    Time frame: 24 months

  7. Rate of complications attributable to the use of any additional NuVasive instruments, implants, or technologies

    Rate of complications attributable to the use of any additional NuVasive instruments, implants, or technologies.

    Time frame: 24 months

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04770571
Lead sponsor
NuVasive
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
May 10, 2022
Primary completion
Sep 2026 (estimated)
Completion
Nov 2028 (estimated)
Last update
Dec 22, 2025

Study contacts

Kyle Malone, MS
study director · NuVasive

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion